Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Previously, the drugs were able to be prescribed through an email chat, from questionnaires or by people sending in photos of ...

PRNewswire Bangalore Karnataka [India] 3 New York-based VJ Group announced the launch of its newest venture VJ Bio a biotech ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

New poll reveals Americans' mixed views on weight-loss drugs for obesity treatment, especially regarding teen use.

In a healthcare market brimming with potential, DarioHealth Corp. * is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it ...

A healthy diet with regular exercise can help with sustainable weight loss. However, the use of Ozempic may contribute to ...